News News & Events News from Morphimmune Targeted therapies developed to reduce lung fibrosis • June 1, 2021 Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs • June 1, 2021 Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models • June 1, 2021 Reprogramming of profibrotic macrophages for treatment of bleomycin‐induced pulmonary fibrosis • June 1, 2021 Latest Press Realease MorphImmune, Inc. Appoints Ronald Martell as President and CEO • June 2, 2021